ArticleMolecular biology reports2026
Inhibition of SARS-CoV-2 spike S1-ACE2 binding interaction and downregulation of ACE2 gene expression by Malaysian stingless bee honey and its bioactive compound, stilbamidine (SDC).
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus infects host cells by binding to angiotensin-converting enzyme 2 (ACE2). Stilbamidine (SDC), a compound identified in Malaysian Kelulut honey (KH), has been reported to exhibit favourable binding affinity towards ACE2. This study aims to determine the effects of KH and SDC on the binding of spike protein to the ACE2 receptor, as well as to assess their modulatory potential on ACE2 gene and protein expression in lung and kidney cells. METHODS AND
resultsKH, SDC, and MLN 4760 (ACE2 inhibitor) were tested using an in vitro spike S1:ACE2 inhibition assay. Their modulatory effects on the ACE2 gene and protein expression were further examined through real-time PCR and western blot analysis. KH inhibited the binding of Spike S1 to ACE2, surpassing MLN4760, with maximum effects (E
conclusionsKH and SDC inhibit the binding of the SARS-CoV-2 spike S1 protein to the ACE2 receptor and reduce ACE2 gene expression. The efficacy of ACE2-targeted interventions may be limited by ACE2 polymorphisms and inter-individual expression differences. Further in vivo studies are needed to confirm their prophylactic and therapeutic potential against SARS-CoV-2 infection.
Indexed as
Identifiers
42033495What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.